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Available online 23 February 2016The human embryonic stem cell line RCe010-A (RC-6) was derived from a frozen and thawed blastocyst volun-
tarily donated as unsuitable and surplus to fertility requirements following ethics committee approved informed
consent under licence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal
pluripotency marker expression and differentiation to the three germ layers in vitro. It has a normal 46XY
male karyotype and microsatellite PCR identity, HLA and blood group typing data are available.
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Aidan.courtney@roslincells.com
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(pre bank at passage 8 on feeders)
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(seed bank at passage 24)pe of resource Biological reagent: Cell line
b-type hESC, research grade
rigin Blastocyst with ICM and Trophoblast
ey transcription factors Oct4 (conﬁrmed by ﬂow cytometry and
immunocytochemistry)
Nanog (conﬁrmed by immunocytochemistry)uthentication See Quality Control Test Summary, Table 1
nk to related literature (direct
URL links and full references)N/Aformation in public databases http://hpscreg.eu/cell-line/RCe010-Aences & RegenerativeMedicine,
ance Crescent, Edinburgh, EH16
. This is an open access article under thcontinued)Name of stem cell constructe CC BY license (http://creativecommRCe010-Athics Informed consent obtained. Scotland A
Research Ethics committee approval
obtained (07/MRE00/56). Conducted under
the UK Human Fertilisation and Embryology
Authority licence no R0136 to centre 0202.Resource details
RCe010-A (RC-6) was derived from a frozen and thawed blastocyst
that was surplus to requirement or unsuitable for clinical use. The cell
linewas derived bywhole embryo outgrowth onmitotically inactivated
human ﬁbroblast (HDF) feeder cells using HDF conditioned medium
and expanded under feeder free conditions.
RCe010-A (RC-6) was shown to be pluripotent by expression of
Oct-4, Nanog, Tra-1-60 and SSEA-4, but low levels of SSEA-1, using im-
munocytochemistry (Table 1, Fig. 1). By ﬂow cytometric analysis, the
expression of pluripotency makers Oct 4 and SSEA-4 was 86.2% and
96.8%, respectively, whereas low expression of the differentiationmark-
er SSEA-1 (5.9%)was observed (Fig. 2). Differentiation to the three germ
layers, endoderm, ectoderm and mesoderm, was demonstrated using
embryoid body formation and expression of the germ layer markers
α-fetoprotein, β-tubulin and muscle actin (Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 2). Blood group genotyping
gave the blood group O1O1 (Table 2).ons.org/licenses/by/4.0/).
Table 1
Summary of quality control testing and results for RC-6 (RCe010-A).
Classiﬁcation Test Purpose Result
Donor screening HIV 1 + 2
Hepatitis B
Hepatitis C
Donor screening for adventitious agents Negative
Identity Microsatellite PCR (mPCR) DNA Proﬁling to give cell line its signature,
gender/species
Performed
Phenotype Immunocytochemisty To assess levels of staining for the
pluripotency markers
Expression of Oct, 4, Nanog,
SSEA-4, Tra-1-60
Flow cytometry Assess antigen levels & cell surface markers
commonly associated with hESC
Oct 3/4: 84.0%
SSEA-4: 99.2%
SSEA-1: 3.8%
Genotype
(Details provided in Table 2)
Blood Group Genotyping
(DNA Analysis)
To establish blood group of the line O1O1
Karyology (G-Banding) Conﬁrmation of normal ploidy by G-banding 46XY
HLA tissue Typing To establish full HLA Type I and II genotype of the line HLA typed Class I and Class II
Microbiology and virology Mycoplasma Mycoplasma testing by RT-qPCR Negative
Endotoxin Screening for Endotoxin levels 1.21 EU/mL
Morphology Photography To capture a visual record of the line Normal
Differentiation potential Embryoid body formation To show differentiation to three germ layers Expression of muscle actin, β-tubulin
and α-feto protein
482 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 481–484Veriﬁcation and authentication
The cell linewas analysed for genome stability by G-banding (Fig. 4)
and showed a normal 46XYmale genotype. The cell line is free frommy-
coplasma contamination as determined by RC-qPCR. Microsatellite PCR
DNA proﬁling for cell identity is shown in Table 2.
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to fertilise/
develop embryos was approved by The Scotland A Research Ethics Com-
mittee and local ethics board at participating fertility clinics and conducted
under licence no R0136 from the UK HFEA with informed donor consent.Fig. 1. RCe010-A (RC-6) expresses pluripotency markers Oct-4, Nanog, SSEA-4 and Tra-1-60, bu
green, cell nuclei are counterstained with DAPI (blue).Cell culture
Frozen embryos were thawed using Embryo Thawing Pack (Origio
(Medicult), Denmark) using standard techniques and cultured in
BlastAssist (Origio) after Day 3 of development. Embryos were cultured
at 36.5–37.5 °C, 5 ± 0.5% CO2, 5 ± 0.5% O2 in drops under parafﬁn oil
(Origio) and transferred to fresh medium at least every 2–3 days.
By Day 8 of development, or when spontaneous hatching occurred,
embryos were placed in derivation conditions consisting of mitotically
inactivated neonatal human dermal ﬁbroblasts (HDFs) (ThermoFisher
Scientiﬁc (Cascade Biologics), Paisley, UK) on tissue culture plastic pre-
coatedwith 2 μg/cm2 human laminin (Sigma Aldrich, Dorset, UK) as per
manufacturer's recommendation. If required, assistedhatchingwasper-
formed by removing the zona pellucidae mechanically using Swemed
Cutting tools (Vitrolife, Göteborg, Sweden).t no signiﬁcant expression of the differentiation maker SSEA-1. Speciﬁc staining shown in
Fig. 2. RCe010-A (RC-6) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in Table 1.
Fig. 3. In vitro differentiation of RCe010-A (RC-6) to ectoderm (β-tubulin III), mesoderm (muscle Actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
counterstained with DAPI (blue).
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(GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine
(ThermoFisher Scientiﬁc). HDF were mitotically inactivated using gamma
irradiation at 50 GY using a Gammacell Elite 1000 machine. For use as a
feeder layer, irradiatedHDFswere plated at 2–50,000 cells/cm2 inHDF con-
ditioned medium (80% Knockout-DMEM, 20% Knockout serum replace-
ment (KOSR), 1 mM glutamine, 0.1 mM β-mercaptoethanol, 1%
nonessential amino acids, and 4 ng/ml human bFGF (all ThermoFisherTable 2
Microsatellite PCR, blood group and HLA tissue typing results for RCe010-A (RC-6).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2
15 15 18 19
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2
X Y lw* lw*
D19S433 1 D19S433 2 THO1 1 THO1 2
14 15 7 7
D5S818 1 D5S818 2 D7S820 1 D7S820 2
10 11 lw* lw*
*Peak falls below threshold to conﬁdently score.
Blood group genotyping
RhD RhC Rhc RhE Rhe
pos pos pos neg pos
Jka Jkb K k M
pos neg neg pos pos
Kp a Kp b Do a Do b ABO
neg pos pos pos O1O
HLA tissue typing
HLA Class I Type HLA-A*01, A*03; B*08, B*44; Cw*05, Cw*07
HLA Class II Type HLA-DRB1*03, DRB1*04; DRB3*01; DRB4*01; DQB1
Comment DRB1*03 is expressed serologically as DR17, DQB1*Scientiﬁc)over24h intervals over7days) supplementedwithanadditional
2 ng/ml humanbFGFCellswere cultured at 36.5–37.5 °C, 5±0.5%CO2, 5±
0.5% O2 and 50% medium exchanged 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and StemprohESC SerumFreeMedium(ThermoFisher Scientiﬁc).
Passaging was performed mechanically using an EZ passage tool
(ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30 wells
of a 6-well plate and cryopreserved in 0.5–1 ml KOSR basedD16S539 1 D16S539 2 D2S1338 1 D2S1338 2
9 10 18 19
D21S11 1 D21S11 2 D18S51 1 D18S51 2
29 32.2 15 16
FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
20 24 12 12
D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 8 9
Fy a Fy b Fy GATA
pos pos neg
N S S
pos neg pos
1
*02, DQB1*03
03 is expressed serologically as DQ7.
Fig. 4. RCe010-A (RC-6) was analysed by Giesma staining of 20 metaphase spreads and showed a normal 46XY male karyotype.
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(ThermoFisher Scientiﬁc ) and 10% DMSO (Origen Biomedical, Texas,
USA)) or Cryostor CS10 (Biolife Solution, Washington, USA).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientiﬁc
(Applied Biosystems)) according to manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
manufacturer's instructions. Brieﬂy, an unknown samplewas compared
with a standard curve of known levels of control endotoxin. An assay
was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and the
CV (%) for the standard curve was ≤10%.
Flow cytometry
Pluripotency was determined using the Human andMouse Pluripo-
tent StemCell Analysis kit (BD,Oxford, UK). Oct 3/4 and SSEA-4were in-
cluded as pluripotencymarkers, and SSEA-1 as a differentiationmarker.
Fixed and permeabilised cells were analysed using a FACS Aria ﬂow
cytometer (BD).
Immunocytochemistry
hESC were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher
Scientiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma), muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark), Oct-4
(1:200; Santa Cruz Biotechnlogy, Texas, USA), Nanog (1:20; R&D Sys-
tems, Abingdon, UK), Tra-1-60, SSEA-1 and SSEA-4 (all 1:50; BD) and
secondary antibodies anti-mouse IgG-FITC (1:200; Sigma), anti mouse
IgG- AlexaFluor 488, anti-goat IgG-AlexaFluor 488, anti-goat IgG-
AlexaFluor-594 and anti-donkey polyclonal AlexaFluor-594 (all 1:200;ThermoFisher Scientiﬁc). Images were acquired using a Zeiss S100
Axiovert ﬂuorescence microscope or Nikon eC1 confocal microscope.
In vitro differentiation
hESC cells were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
EBs generated in ultra low attachment plates (Corning) for 7 days before
being transferred into EBmedium (20% FBS (GE Healthcare (PAA)), 80%
KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1%
nonessential amino acids (all ThermoFisher Scientiﬁc)), on glass slide
tissue culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with
0.5% gelatin (Sigma) at 0.1 ml/cm2 for 14 days.
Genomic analysis
All outsourced assayswere carried out under aQuality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.
Microsatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular
Diagnostics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK) Live cells at 60–70% conﬂuency were shipped over-
night in warm containers, ﬁxed and analysed by standard G-banding
analysis. For research grade lines, 20 spreads were analysed.
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